Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas – A systematic review and meta-analysis

#3670

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC has shown efficacy in the metastatic setting of pheochromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.

Aim(s): A subsequent meta-analysis was performed to evaluate the pooled effect size on response to PRRT. Secondary endpoints were description of patients’ genetic characteristics, hematologic toxicity, time-to-outcome.

Materials and methods: Keywords used for searching were “pheochromocytoma” AND/OR “paraganglioma” AND/OR “therapy”. To avoid spurious and heterogeneous results, studies reporting on multiple PRRT agents and/or plus concomitant chemotherapy or radiosensitizers were excluded. The pooled effect of the various studies was estimated with both a mixed effects model and a random effects model. To assess the degree of heterogeneity between studies, the I2 statistic and the relative p value were taken into consideration, considering as significant the heterogeneity between studies in case of p<0.10. The presence of possible publication bias was assessed by funnel plot.

Conference:

Presenting Author: Marretta A

Authors: Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O,

Keywords: PRRT, Pheochromocytoma, Paraganglioma, Neuroendocrine Tumor, Meta-analysis,